Establishing a miRNA panel for hepatocellular carcinoma screening through a multicenter study
Summary: Most patients with hepatocellular carcinoma (HCC) are often diagnosed at advanced stages, limiting the effectiveness of curative treatments. In a multicenter study involving 522 patients with HCC and liver cirrhosis, predominantly with hepatitis B virus infection, we evaluated plasma microR...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004225012477 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849703974875168768 |
|---|---|
| author | Kelvin Ka Ki Ng Yanjun Lu Jia Qiu Zihan Yang Xiaoyu Zhou Hui Xie Zhihang Zhou Mengsu Yang |
| author_facet | Kelvin Ka Ki Ng Yanjun Lu Jia Qiu Zihan Yang Xiaoyu Zhou Hui Xie Zhihang Zhou Mengsu Yang |
| author_sort | Kelvin Ka Ki Ng |
| collection | DOAJ |
| description | Summary: Most patients with hepatocellular carcinoma (HCC) are often diagnosed at advanced stages, limiting the effectiveness of curative treatments. In a multicenter study involving 522 patients with HCC and liver cirrhosis, predominantly with hepatitis B virus infection, we evaluated plasma microRNAs (miRNAs) as potential liquid biopsy biomarkers for early HCC screening. Significant upregulation of 18 miRNAs in HCC patients was confirmed across three stages. We conducted a meta-analysis integrating our results with existing literature based on pooled effect size, successfully confirming the upregulation of 4 miRNAs in our findings. Employing an explainable machine learning approach, we established a 5-miRNA panel (miR-361-5p+ miR-130a-3p+ miR-27a-3p+ miR-30d-5p+ miR-193a-5p) with alpha-fetoprotein (AFP) for HCC screening. This combined panel demonstrated superior diagnostic performance compared to AFP alone (AUC: 0.924 vs. 0.794; p < 0.001) in distinguishing HCC patients in the testing and validation set, highlighting its potential as a promising minimally invasive screening method for HCC. |
| format | Article |
| id | doaj-art-ee55975853a94726b5efc74c0ec95bb8 |
| institution | DOAJ |
| issn | 2589-0042 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | iScience |
| spelling | doaj-art-ee55975853a94726b5efc74c0ec95bb82025-08-20T03:16:57ZengElsevieriScience2589-00422025-08-0128811298610.1016/j.isci.2025.112986Establishing a miRNA panel for hepatocellular carcinoma screening through a multicenter studyKelvin Ka Ki Ng0Yanjun Lu1Jia Qiu2Zihan Yang3Xiaoyu Zhou4Hui Xie5Zhihang Zhou6Mengsu Yang7Department of Precision Diagnostic and Therapeutic Technology, City University of Hong Kong Futian Research Institute, Shenzhen, Guangdong, China; Department of Biomedical Sciences, and Tung Biomedical Sciences Center, City University of Hong Kong, 83 Tat Chee Avenue, Kowloon, Hong Kong SAR, ChinaDepartment of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Precision Diagnostic and Therapeutic Technology, City University of Hong Kong Futian Research Institute, Shenzhen, Guangdong, China; Department of Biomedical Sciences, and Tung Biomedical Sciences Center, City University of Hong Kong, 83 Tat Chee Avenue, Kowloon, Hong Kong SAR, ChinaDepartment of Precision Diagnostic and Therapeutic Technology, City University of Hong Kong Futian Research Institute, Shenzhen, Guangdong, China; Department of Biomedical Sciences, and Tung Biomedical Sciences Center, City University of Hong Kong, 83 Tat Chee Avenue, Kowloon, Hong Kong SAR, ChinaDepartment of Precision Diagnostic and Therapeutic Technology, City University of Hong Kong Futian Research Institute, Shenzhen, Guangdong, China; Department of Biomedical Sciences, and Tung Biomedical Sciences Center, City University of Hong Kong, 83 Tat Chee Avenue, Kowloon, Hong Kong SAR, ChinaSenior Department of Oncology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China; Corresponding authorDepartment of Precision Diagnostic and Therapeutic Technology, City University of Hong Kong Futian Research Institute, Shenzhen, Guangdong, China; Department of Gastroenterology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China; Corresponding authorDepartment of Precision Diagnostic and Therapeutic Technology, City University of Hong Kong Futian Research Institute, Shenzhen, Guangdong, China; Department of Biomedical Sciences, and Tung Biomedical Sciences Center, City University of Hong Kong, 83 Tat Chee Avenue, Kowloon, Hong Kong SAR, China; Corresponding authorSummary: Most patients with hepatocellular carcinoma (HCC) are often diagnosed at advanced stages, limiting the effectiveness of curative treatments. In a multicenter study involving 522 patients with HCC and liver cirrhosis, predominantly with hepatitis B virus infection, we evaluated plasma microRNAs (miRNAs) as potential liquid biopsy biomarkers for early HCC screening. Significant upregulation of 18 miRNAs in HCC patients was confirmed across three stages. We conducted a meta-analysis integrating our results with existing literature based on pooled effect size, successfully confirming the upregulation of 4 miRNAs in our findings. Employing an explainable machine learning approach, we established a 5-miRNA panel (miR-361-5p+ miR-130a-3p+ miR-27a-3p+ miR-30d-5p+ miR-193a-5p) with alpha-fetoprotein (AFP) for HCC screening. This combined panel demonstrated superior diagnostic performance compared to AFP alone (AUC: 0.924 vs. 0.794; p < 0.001) in distinguishing HCC patients in the testing and validation set, highlighting its potential as a promising minimally invasive screening method for HCC.http://www.sciencedirect.com/science/article/pii/S2589004225012477Molecular biologyCancer |
| spellingShingle | Kelvin Ka Ki Ng Yanjun Lu Jia Qiu Zihan Yang Xiaoyu Zhou Hui Xie Zhihang Zhou Mengsu Yang Establishing a miRNA panel for hepatocellular carcinoma screening through a multicenter study iScience Molecular biology Cancer |
| title | Establishing a miRNA panel for hepatocellular carcinoma screening through a multicenter study |
| title_full | Establishing a miRNA panel for hepatocellular carcinoma screening through a multicenter study |
| title_fullStr | Establishing a miRNA panel for hepatocellular carcinoma screening through a multicenter study |
| title_full_unstemmed | Establishing a miRNA panel for hepatocellular carcinoma screening through a multicenter study |
| title_short | Establishing a miRNA panel for hepatocellular carcinoma screening through a multicenter study |
| title_sort | establishing a mirna panel for hepatocellular carcinoma screening through a multicenter study |
| topic | Molecular biology Cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2589004225012477 |
| work_keys_str_mv | AT kelvinkaking establishingamirnapanelforhepatocellularcarcinomascreeningthroughamulticenterstudy AT yanjunlu establishingamirnapanelforhepatocellularcarcinomascreeningthroughamulticenterstudy AT jiaqiu establishingamirnapanelforhepatocellularcarcinomascreeningthroughamulticenterstudy AT zihanyang establishingamirnapanelforhepatocellularcarcinomascreeningthroughamulticenterstudy AT xiaoyuzhou establishingamirnapanelforhepatocellularcarcinomascreeningthroughamulticenterstudy AT huixie establishingamirnapanelforhepatocellularcarcinomascreeningthroughamulticenterstudy AT zhihangzhou establishingamirnapanelforhepatocellularcarcinomascreeningthroughamulticenterstudy AT mengsuyang establishingamirnapanelforhepatocellularcarcinomascreeningthroughamulticenterstudy |